Reported Earlier, 4DMT And Otsuka Pharmaceutical Sign $85M Upfront License Deal With Up To $336M In Milestones To Develop And Commercialize 4D-150 Across Asia-Pacific
Benzinga Newsdesk 1 year ago
News
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336
- 4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration
- Up to $336 million in potential regulatory and commercial milestones and tiered double-digit royalties depending on net sales in Otsuka's territories
- Proceeds and cost sharing expected to support global Phase 3 clinical trial in DME and pre-commercial activities